Faculty
Oncology Division
Alphabetical list (active faculty):   
Nusayba A. Bagegni

Nusayba A. Bagegni, MD

Assistant Professor

Department of Medicine

Oncology Division

Medical Oncology

Clinical Interests

  • Breast cancer

Research Interests

  • Breast cancer clinical trials
  • Developmental therapeutics
  • HER2 positive breast cancer
  • Metastatic breast cancer

Contact

  • 314-362-5654 (office)
  • 314-362-7086 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor, Mid-Campus Center (office)

Research

Study Chair for National Cancer Institute Cancer Therapy Evaluation Program Experimental Therapeutics Clinical Trials Network Trial 10382: A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer (NCT04345913).

Site Principal Investigator for Phase II ELAINE study: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation. Siteman Cancer Center, Washington University School of Medicine.

Site Principal Investigator for ECOG-ACRIN EA1181 CompassHER2-pCR Trial: Comprehensive use of Pathologic response assessment to optimize therapy in HER-2-positive breast cancer. Siteman Cancer Center, Washington University School of Medicine.

Site Principal Investigator for Alliance CompassHER2 Residual Disease (RD) Trial, a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and TucatinibT-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer. Siteman Cancer Center, Washington University School of Medicine.

Site Principal Investigator for Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06). Siteman Cancer Center, Washington University School of Medicine.

Site Principal Investigator for Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer. Siteman Cancer Center, Washington University School of Medicine.

Site Principal Investigator for Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM-1 or T-DXd, and/or Tucatinib-containing Regimens (ACE-Breast-03). Siteman Cancer Center, Washington University School of Medicine.